Sign in
WithdrawnPhase 2

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Key facts

Who runs it
The First Affiliated Hospital of Soochow University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 2
Started
26 May 2026
Ended
28 May 2026
Type of study
Interventional
Treatments tested
  • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
Record updated
3 June 2026
Why it stopped
The study did not initiate because manufacturing of the CAR-T product failed.

Who can take part

Age
6 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Voluntary signing of informed consent and good compliance
  • Age ≥ 6 years
  • Previously treated with 2 or more lines of therapy
  • Has a measurable target lesion
  • ECOG 0-1#
  • Have appropriate organ function, subject to the following criteria (except for abnormal liver function due to tumor infiltration): AST≤3 times upper limit of normal#ALT≤3 times upper limit of normal# TB≤2 times ULN, unless combined with Gilbert's syndrome #Patients with Gilbert's syndrome with TB≤ 3 times ULN and DB≤ 1.5 times ULN can be include # Scr ≤1.5 times ULN or CCr≥60 ml/min# Lung function≤Level 1; dyspnea(CTCAE v5.0),and blood oxygen saturation without oxygen absorption> 91%# INR≤1.5 times ULN# aPTT≤1.5 times ULN
  • negative blood/urine pregnancy test in women of childbearing age within 7 days prior to cell infusion, and any male and female patients of childbearing potential must agree to use an effective method of contraception throughout the study and for at least six months after the study treatment is administered
  • Pass the T-cell amplification test
  • Have adequate venous access to single or venous blood and no other contraindications to leukocyte isolation
  • Estimated survival time ≥3 months

Who cannot take part

  • Have used immunosuppressants or hormones within 2 weeks prior to signing informed consent, or plan to have to use immunosuppressants or high-dose hormones (e.g. prednisone >15mg) after signing informed consent, specifically systemic treatment, excluding treatment with topical or inhaled corticosteroids
  • Previous or current CNS disease other than this disease, such as seizures, cerebrovascular ischaemia/hemorrhage, dementia, cerebellar disease or any CNS-related autoimmune disease
  • A history of cardiac angioplasty or stent placement within 12 months prior to signing the informed consent form, or a history of myocardial infarction, unstable angina or other clinically significant heart disease
  • Have had a severe tachyphylaxis to any of the drugs to be used in this study
  • Live vaccination within 6 weeks prior to screening
  • Received an allogeneic hematopoietic stem cell transplant within 6 months prior to signing the informed consent form
  • Participated in an investigational clinical trial of any other drug within 30 days prior to signing the informed consent form
  • Prior malignancy (other than Relapsed Refractory B-cell Non-Hodgkin's Lymphoma), except for cured malignant tumors with no active lesions for 3 years; Adequate treatment of inactive lesions in non-melanoma skin cancer, malignant tonsilloma or carcinoma in situ
  • The presence of bacterial, fungal, viral, mycoplasma or other types of infection that, in the judgment of the investigator, are difficult to control
  • HIV, Syphilis or COVID-19 infection
  • Active hepatitis B or active hepatitis C
  • Active autoimmune diseases
  • Active acute or chronic graft-versus-host disease (GVHD) at the time of signing the informed consent form
  • Conditions deemed by the researcher to be inappropriate for participation in this clinical trial
  • Patients with primary immunodeficiency
  • Pregnant or breasting-feeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.

The group in the trial

  • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ TargetsTreatment being tested

    Chimeric antigen receptor T cells targeting Igβ targets (CAR-T)

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clinical Study of the Safety, Tolerability and Preliminary Efficacy of Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets in Patients With Igβ-positive Refractory Relapsed Non-Hodgkin's Lymphoma
Record updated
3 June 2026